TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Fujirebio Diagnostics AB
Closing information (x1000 EUR)
| Closing information | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) |
| Turnover |
27,868
|
27,570
|
25,645 |
| Financial expenses |
376
|
7
|
46 |
| Earnings before taxes |
14,557
|
15,734
|
13,481 |
| EBITDA |
15,035
|
16,307
|
14,000 |
| Total assets |
67,217
|
57,165
|
59,513 |
| Current assets |
41,321
|
29,754
|
28,726 |
| Current liabilities |
10,539
|
4,416
|
6,148 |
| Equity capital |
55,966
|
52,070
|
52,719 |
| - share capital |
56
|
57
|
62 |
| Employees (average) |
89
|
86
|
75 |
Financial ratios
| Fiscal year | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) |
| Solvency |
83.3%
|
91.1%
|
88.6% |
| Turnover per employee |
313
|
321
|
342 |
| Profit as a percentage of turnover |
52.2%
|
57.1%
|
52.6% |
| Return on assets (ROA) |
22.2%
|
27.5%
|
22.7% |
| Current ratio |
392.1%
|
673.8%
|
467.2% |
| Return on equity (ROE) |
26.0%
|
30.2%
|
25.6% |
| Change turnover |
894
|
4,057
|
1,442 |
| Change turnover % |
3%
|
17%
|
6% |
| Chg. No. of employees |
3
|
11
|
4 |
| Chg. No. of employees % |
3%
|
15%
|
6% |
Total value of public sale
| Fiscal year | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.